Evidence map›Paper›PMID 41469296›Full record

GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2026

Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

J S Deutsch, R A Scolyer, E Burton, K J Busam, K Y Chen, A Cimino-Mathews, T R Cottrell, C E de Andrea, P O Fiset, G V Long and 13 more

Abstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

J S DeutschDepartments of Dermatology, Pathology, and Oncology, and The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, USA.
R A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital and NSW Health Pathology, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
E BurtonThe University of Texas MD Anderson Cancer Center, Houston, USA.
K J BusamDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
K Y ChenDepartments of Dermatology, Johns Hopkins University SOM, Baltimore, USA.
A Cimino-MathewsPathology, Johns Hopkins University SOM, Baltimore, USA.
T R CottrellQueen's University Sinclair Cancer Research Institute, Kingston, Canada.
C E de AndreaPathology, University of Navarra, Pamplona, Spain.
P O FisetDepartment of Pathology, McGill University Health Centre, Montréal, Canada.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Mater and Royal North Shore Hospitals, Sydney, Australia.
J MessinaDepartment of Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA.
R V RawsonMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital and NSW Health Pathology, The University of Sydney, Sydney, Australia.
R SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium; Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
C M SchürchDepartment of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen, Tübingen, Germany; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
R R SeethalaUniversity of Pittsburgh Medical Center, Department of Pathology, Pittsburgh, USA.
L M ShollDepartment of Pathology, Brigham and Women's Hospital, Boston, USA.
S SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, USA.
S L TopalianDepartment of Surgery, Johns Hopkins University SOM, Baltimore, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, USA; Johns Hopkins Kimmel Cancer Center, Baltimore, USA.
B A van de WielDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
X XuAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
J E GershenwaldDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M T TetzlaffDepartments of Pathology and Dermatology, Dermatopathology and Oral Pathology Unit, University of California San Francisco, San Francisco, USA.
J M TaubeBloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University SOM, Baltimore, USA; Departments of Dermatology, Pathology, and Oncology, The Mark Foundation Center for Advanced Imaging and Genomics, Baltimore, USA. Electronic address: jtaube1@jhmi.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Michael Jason de la Cruz · 1985 to 2026
$347.4M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heath Devin Skinner · 2004 to 2026
$49.6M
PD-1/PD-L1 modulation in cancer therapyR01CA142779 · NCI · JOHNS HOPKINS UNIVERSITY · PI PARDOLL, DREW M., TAUBE, JANIS M · 2010 to 2025
$8.2M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA097190NCI NIH HHS R01 CA142779
6 · The paper itself

Abstract

backgroundPractice-changing clinical trials for novel therapeutic regimens administered in the neoadjuvant setting have been reported for multiple cancer types, bringing this treatment strategy to the forefront for patients with high-risk surgically resectable disease. Previously, tumor-type- or therapy-type-specific scoring systems were used for pathologic response assessment. The goal of this effort is to update, harmonize, and standardize the emerging system(s) for pathologic response assessment and data capture. MATERIALS AND

methodsLeaders in pathology, oncology, and surgery, including those from the Society for Immunotherapy of Cancer's Pan-tumor Harmonization of Pathologic Response Assessment (PATHdata) efforts and the International Neoadjuvant Melanoma Consortium (INMC), convened to develop updated consensus guidelines for pathologic response assessment, including specimen handling and tissue submission, scoring, and reporting. This paper builds upon previous recommendations, which are updated based on histologic features associated with patient outcomes. Specific attention was paid to commonalities across tumor types, as well as tumor-type-specific considerations.

resultsA revised and standardized approach to tissue submission is recommended, including total submission of tumors ≤3 cm in size for histologic analysis. Additional guidance is provided for larger tumors. Pathologic response is quantified through assessments of percentage of residual viable tumor (%RVT), necrosis, and regression. Descriptions of histologic features to be scored are provided together with a standardized reporting template. Recommendations regarding collecting additional key datapoints are also made, to allow continued, extended validation of this pan-tumor approach.

conclusionsAs pathologic response emerges as a surrogate endpoint for long-term clinical outcomes and to help inform adaptive adjuvant therapy decisions in routine clinical care, standardization is critical to facilitate consistent and reliable application. This pan-tumor approach to scoring and reporting supports robust stratification of patient outcomes, facilitates comparisons across clinical trials and tumor types, enhances data collection, and establishes a foundation for identifying additional, clinically meaningful %RVT cut points.

Indexed as

Neoadjuvant TherapyNeoplasmsPractice Guidelines as TopicHumansguidelinesmelanomaneoadjuvantpan-tumorpathologic response%RVT

Identifiers

PMID41469296
PMCPMC13318440

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.